Whitepaper and App Notes

Fast-Tracking Biomarker Discovery into Clinical Research for Parkinson’s Disease at Dartmouth

How Dartmouth Geisel School of Medicine and Quanterix Accelerated NLRP3 Detection

Developing novel biomarker assays for neurodegenerative research can be complex, time-intensive, and require deep expertise. In collaboration with the Geisel School of Medicine at Dartmouth and the Michael J. Fox Foundation, the Quanterix Accelerator Lab helped develop a high-sensitivity Simoa® assay to measure NLRP3 inflammasome levels—a key marker of neuroinflammation in Parkinson’s disease.

Watch this short video highlighting the collaboration and its impact on biomarker research:

In this case study, learn how:

  • Dr. Matthew Havrda’s research team overcame assay sensitivity challenges
  • Simoa technology enabled the detection of NLRP3 in previously undetectable samples
  • Custom assay development accelerated biomarker translation for clinical research

Download the full case study to explore how Simoa ultra-sensitive biomarker detection and custom assay development are advancing neurodegenerative research.